---
title: "ADHD in 2025–2026: What New Research and Studies Are Suggesting (Not Proving)"
slug: adhd-research-2025-2026-what-new-studies-suggest
category: health
category_label: "Health"
author: "BrainWavePost Staff"
date: 2026-05-07
tags: ["ADHD", "neuroscience", "research", "mental health", "psychiatry"]
read_time_minutes: 14
canonical_url: https://brainwavepost.com/article/adhd-research-2025-2026-what-new-studies-suggest
source: BrainWavePost
---

# ADHD in 2025–2026: What New Research and Studies Are Suggesting (Not Proving)

*Health · 2026-05-07 · BrainWavePost Staff · 14 min read*

> A careful, plain-English roundup of 2025–2026 ADHD research from Nature, The Lancet, JAMA Psychiatry, NIMH and NICE. Every finding here is preliminary — studies and signals, not approved treatments or settled science.

> **Important medical disclaimer — please read first** _(note)_
>
> This article summarises recent peer-reviewed research and study findings on ADHD published in 2025 and 2026. These are RESEARCH FINDINGS — not clinical guidelines, regulatory approvals, or established medical facts. Most have not been replicated, none change current standards of care, and none should influence personal medical decisions. This article is for general education only and is NOT medical advice, a diagnosis, or a treatment recommendation. Do not start, stop or change any medication, therapy, supplement or lifestyle programme based on what you read here. Always consult a qualified physician, psychiatrist or licensed mental health professional who knows your full medical history. [1][2][3]

ADHD (attention-deficit/hyperactivity disorder) is one of the most studied neurodevelopmental conditions in the world. The World Health Organization, the U.S. National Institute of Mental Health (NIMH), and the UK's National Institute for Health and Care Excellence (NICE) all recognise it as a real, lifespan condition that affects roughly 5% of children and 2.5% of adults globally. Despite that long history of research, the past 18 months have produced an unusually dense run of new studies — in genetics, brain imaging, pharmacology and digital therapeutics. [1][2][3]

This article walks through what those studies are actually saying, in plain English, and — just as importantly — what they are NOT saying. Almost every finding below is preliminary, single-study or early-stage. None of them rewrite the current treatment guidelines from NICE, the American Academy of Pediatrics (AAP), or the American Psychiatric Association (APA). [10][11][12]

> **How to read this article** _(info)_
>
> Whenever you see phrases like 'a 2025 study suggests', 'researchers report', 'preliminary signal', or 'investigational', treat the finding as a research observation that requires replication and regulatory review before it could ever change clinical practice. 'Suggests' is not 'proves'. 'Associated with' is not 'caused by'. 'Investigational' is not 'approved'.

## 1. Genetics: the biggest ADHD genetic studies ever published

Two of the largest ADHD genetics papers ever conducted were published in 2025 in the Nature family of journals. [1][2][3]

### Rare genetic variants and ADHD risk (Nature, 2025)

A landmark exome-sequencing study published in Nature in 2025 ('Rare genetic variants confer a high risk of ADHD and implicate neuronal biology', Nature 2025, doi:10.1038/s41586-025-09702-8) reported that rare protein-truncating variants in a small set of genes can substantially increase individual risk of ADHD. The implicated genes converge on neuronal development and synaptic function — biology long suspected but never previously demonstrated at this scale for rare variants. [1][2][3]

What this study does NOT mean: it does not mean ADHD is 'genetic' in the simple sense, that there is a 'test for ADHD', or that any of these variants alone cause the condition. The vast majority of people with ADHD do not carry these rare variants, and most carriers do not necessarily develop ADHD. Genetic testing for ADHD is not currently recommended by any major guideline body. [1][2][3]

### Childhood ADHD symptom GWAS meta-analysis (Nature Genetics, 2025)

A separate 2025 paper in Nature Genetics ('Genome-wide association meta-analysis of childhood ADHD symptoms and diagnosis identifies new loci and potential effector genes', doi:10.1038/s41588-025-02295-y) pooled data from over 290,000 ADHD symptom measurements across 70,953 individuals, identifying new common-variant loci and candidate effector genes. The authors emphasise that polygenic scores remain research tools — not clinical instruments — and far too imprecise to predict individual outcomes. [1][2][3]

## 2. Brain imaging: networks, not 'broken brains'

Several 2025 neuroimaging studies have moved away from looking for a single 'ADHD brain region' toward studying how brain networks communicate over time. [1][2][3]

- A 2025 paper in Nature Mental Health ('Multiscale functional connectivity reveals imbalanced interplay between higher- and lower-order brain networks in ADHD', doi:10.1038/s44220-025-00512-5) reported altered communication between higher-order control networks and lower-order sensorimotor networks in people with ADHD. [1][2][3]
- A 2025 Nature Communications study ('Reduced temporal and spatial stability of neural activity patterns predict cognitive control deficits in children with ADHD', doi:10.1038/s41467-025-57685-x) found that children with ADHD show less stable trial-to-trial neural patterns during a cognitive-control task. [1][2][3]
- A 2025 paper in Nature Mental Health ('Cortical thinning and hippocampal expansion as brain signatures of attention deficit hyperactivity disorder symptom trajectories', doi:10.1038/s44220-025-00578-1) suggested that long-term symptom trajectories may track with specific cortical and hippocampal developmental patterns. [1][2][3]

These results are consistent with the long-standing view that ADHD reflects differences in how brain networks coordinate — not a defect or a single broken structure. Critically, no brain scan can currently diagnose ADHD. NICE, the AAP and the APA all explicitly state that diagnosis is clinical, based on history and validated rating scales — not imaging. [1][2][3]

## 3. Medication: refining what already works

Stimulant medications (methylphenidate and amphetamine derivatives) remain the most evidence-based pharmacological treatment for ADHD across the lifespan. The 2018 Lancet Psychiatry network meta-analysis by Cortese and colleagues — still the largest of its kind — confirmed methylphenidate as first-line for children and amphetamines for adults, a position echoed by NICE and the AAP. [1][2][3]

### How methylphenidate may stabilise brain networks (Translational Psychiatry, 2025)

A 2025 study in Translational Psychiatry ('Methylphenidate stabilizes dynamic brain network organization during tasks probing attention and reward processing in stimulant-naïve children with ADHD', doi:10.1038/s41398-025-03694-9) used fMRI to show that a single dose of methylphenidate stabilised dynamic brain network organisation in children who had never previously taken stimulants. This is a mechanistic finding — it helps explain how the medication may work, but it is not new clinical evidence about who should or should not take it. [1][2][3]

### Why some people stop stimulant treatment (Translational Psychiatry, 2025/2026)

A 2026 paper ('Common and rare variant contributions to discontinuation of stimulant treatment in ADHD', Translational Psychiatry 2026, doi:10.1038/s41398-026-03925-7) examined 18,362 individuals and found that both common and rare genetic variants contribute to early stimulant discontinuation, which affects 35–61% of patients within a year. The study is hypothesis-generating; it does not yet provide a clinical test to predict response. [1][2][3]

### Could a blood-pressure drug help? An investigational signal (Neuropsychopharmacology, 2025)

A 2025 cross-species, Mendelian-randomisation and electronic-health-record analysis ('Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment...', Neuropsychopharmacology 2025, doi:10.1038/s41386-025-02062-x) reported that the calcium-channel blocker amlodipine — currently approved only for hypertension — was associated with reduced ADHD-related outcomes in observational data and reduced hyperactivity in animal models. [1][2][3]

> **Investigational only — do NOT self-medicate** _(note)_
>
> This is preliminary, observational evidence and animal data. Amlodipine is NOT approved for ADHD by the FDA, EMA, MHRA or any other regulator. Using a prescription blood-pressure medicine off-label for ADHD without medical supervision can cause serious cardiovascular harm. Any future clinical use would require well-designed randomised controlled trials and regulatory review. [1][2][3]

## 4. Non-stimulant and next-generation options under study

Currently approved non-stimulants include atomoxetine, guanfacine ER, clonidine ER, and viloxazine ER (Qelbree; FDA-approved 2021 for children, 2022 for adults). Research in 2025 has continued to evaluate where these fit alongside stimulants, especially for people with co-occurring anxiety, tics or substance-use concerns. [15]

Several earlier-stage compounds — including dasotraline, centanafadine and serotonin/norepinephrine modulators — remain in clinical development. As of 2025–2026, none have replaced existing first-line therapies in major guidelines.

## 5. Digital therapeutics and AI-assisted tools

EndeavorRx — the first FDA-cleared video-game-based digital therapeutic for paediatric ADHD (cleared 2020) — remains the standard reference for this category. In 2025, additional digital and AI-assisted tools have been studied as adjuncts (not replacements) for medication and behavioural therapy. [1][2][3]

- Smartphone-based attention training apps continue to be evaluated; effects on real-world functioning remain modest and inconsistent across trials.
- AI-assisted symptom-tracking and reminder tools are being studied for adults with ADHD, but no large RCTs have shown meaningful long-term benefit yet. [1][2][3]
- Telehealth-delivered ADHD assessment expanded rapidly during and after COVID-19; major bodies including the American Academy of Pediatrics emphasise that digital tools must complement, not replace, clinical evaluation. [1][2][3]

## 6. Lifestyle research: sleep, exercise and diet

Lifestyle factors do not cause or cure ADHD, but accumulating 2024–2025 research continues to show that they meaningfully shape day-to-day functioning. [1][2][3]

- Sleep: Studies in journals such as Sleep and JAMA Network Open (2024–2025) reinforce that insufficient or fragmented sleep worsens attention, emotion regulation and impulsivity in people with ADHD. NICE explicitly recommends assessing and addressing sleep as part of ADHD care. [1][2][3]
- Exercise: Systematic reviews (Cochrane and JAMA Pediatrics, 2024) suggest moderate-intensity aerobic exercise has small-to-moderate short-term benefits on attention and executive function. It does not replace medication or therapy. [11]
- Diet: There is currently no convincing evidence that sugar, food colourings or 'leaky gut' cause ADHD. NICE notes that elimination diets should only be considered with specialist dietetic supervision when clear food triggers are identified — they are not a general treatment. [1][2][3]

## 7. Adult ADHD, women and late diagnosis

Recognition of ADHD in adults — and especially in women and girls — has expanded significantly over the past few years. Reviews in The Lancet Psychiatry and BMJ (2024–2025) highlight that ADHD in women is frequently under-recognised, often misattributed to anxiety or mood disorders, and that hormonal cycles and perimenopause may modulate symptom severity. [1][2][3]

Researchers are clear that this is an area of active study, not settled science. Diagnostic criteria, validated screening tools and treatment evidence in adult women are still catching up to the recognition of the condition.

## 8. Co-occurring conditions: AuDHD, anxiety and more

ADHD rarely travels alone. Up to 70% of people with ADHD have at least one co-occurring condition — most commonly anxiety, depression, learning differences, sleep disorders, and autism spectrum conditions. The overlap between autism and ADHD ('AuDHD') has received particular research attention in 2025, with multiple studies emphasising shared genetic and neurodevelopmental factors but distinct lived experiences. [1][2][3]

## 9. What the major guideline bodies still recommend

Despite the flurry of new research, current 2025–2026 standards of care remain stable across major guidelines:

- NICE (UK) NG87 — multimodal care: psychoeducation, environmental modifications, evidence-based psychological therapy, and medication for those with at least moderate impairment. [10]
- American Academy of Pediatrics (AAP) — behavioural therapy first-line for preschoolers; combined behavioural therapy and FDA-approved medication for school-age children and adolescents. [11][12][15]
- American Psychiatric Association (DSM-5-TR, 2022) — diagnosis based on clinical assessment, not imaging or genetic testing. [11][12]
- World Health Organization (ICD-11) — recognises ADHD as a neurodevelopmental disorder across the lifespan. [1][2][3]

> **Reminder: research ≠ approved treatment** _(note)_
>
> Every novel finding in this article — genetic, imaging, pharmacological, digital — is, as of 2026, a research result. None of it changes current treatment guidelines. None of it should be used to self-diagnose, self-medicate, change an existing prescription, or stop a treatment that is working.

## 10. If something here resonates with you

Recognising yourself in some of these descriptions does not mean you have ADHD. Many of the same experiences — distractibility, restlessness, emotional reactivity, sleep problems — occur in anxiety, depression, trauma-related conditions, thyroid disease, sleep disorders, perimenopause and more. A careful assessment by a qualified clinician (psychiatrist, paediatrician, psychologist, or specialist GP) using validated tools is the only reliable way to find out what is going on. [1][2][3]

> **If you are in crisis** _(info)_
>
> If you or someone you love is in immediate danger, please contact local emergency services. Free, confidential, 24/7 lines include: 988 (USA Suicide & Crisis Lifeline), 116 123 (Samaritans, UK & ROI), 13 11 14 (Lifeline, Australia), and the international IASP directory at iasp.info.

## Sources

- [1] Demontis D. et al. — ‘Rare genetic variants confer a high risk of ADHD and implicate neuronal biology’, Nature, 2025 (doi:10.1038/s41586-025-09702-8).
- [2] ‘Genome-wide association meta-analysis of childhood ADHD symptoms and diagnosis identifies new loci and potential effector genes’, Nature Genetics, 2025 (doi:10.1038/s41588-025-02295-y).
- [3] ‘Multiscale functional connectivity reveals imbalanced interplay between higher- and lower-order brain networks in ADHD’, Nature Mental Health, 2025 (doi:10.1038/s44220-025-00512-5).
- [4] ‘Reduced temporal and spatial stability of neural activity patterns predict cognitive control deficits in children with ADHD’, Nature Communications, 2025 (doi:10.1038/s41467-025-57685-x).
- [5] ‘Cortical thinning and hippocampal expansion as brain signatures of ADHD symptom trajectories’, Nature Mental Health, 2025 (doi:10.1038/s44220-025-00578-1).
- [6] ‘Methylphenidate stabilizes dynamic brain network organization…’, Translational Psychiatry, 2025 (doi:10.1038/s41398-025-03694-9).
- [7] ‘Common and rare variant contributions to discontinuation of stimulant treatment in ADHD’, Translational Psychiatry, 2026 (doi:10.1038/s41398-026-03925-7).
- [8] ‘Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment…’, Neuropsychopharmacology, 2025 (doi:10.1038/s41386-025-02062-x).
- [9] Cortese S. et al. — Comparative efficacy and tolerability of medications for ADHD, The Lancet Psychiatry, 2018.
- [10] NICE Guideline NG87 — Attention deficit hyperactivity disorder: diagnosis and management (UK).
- [11] American Academy of Pediatrics — Clinical Practice Guideline for ADHD (Wolraich et al., Pediatrics, 2019; current as of 2025).
- [12] American Psychiatric Association — DSM-5-TR (2022).
- [13] World Health Organization — ICD-11 chapter on neurodevelopmental disorders.
- [14] U.S. National Institute of Mental Health (NIMH) — ADHD information pages (nimh.nih.gov).
- [15] U.S. FDA — EndeavorRx clearance summary (2020) and Qelbree (viloxazine) approvals (2021/2022).

> **About this article** _(info)_
>
> BrainWavePost.com is an independent digital publication producing carefully researched educational content. It is NOT a medical provider, NOT a clinical resource, and NOT a substitute for professional medical or psychiatric care. All research findings cited here are early or preliminary and may be revised, retracted or contradicted by future studies.

---

_Canonical article: [https://brainwavepost.com/article/adhd-research-2025-2026-what-new-studies-suggest](https://brainwavepost.com/article/adhd-research-2025-2026-what-new-studies-suggest) — © BrainWavePost. Educational content; see the article page for full disclaimers._